Berberine
Isoquinoline alkaloid that activates AMP-activated protein kinase (AMPK) in liver, muscle, and adipose tissue. AMPK activation improves insulin sensitivity by increasing GLUT4 translocation, enhances mitochondrial biogenesis, and inhibits hepatic gluconeogenesis. Also modulates gut microbiome composition, increasing short-chain fatty acid-producing bacteria. Head-to-head trials show glycemic control comparable to metformin at equivalent doses.
Three tiers ordered by aggressiveness. Tier chips on every OPTIMIZE intervention let you filter the catalog by your evidence tolerance.
- fasting-glucose
- hba1c
- fasting-insulin
- homa-ir
- lipid-panel
- alt
- ast
- pregnancy
- concurrent-metformin-without-monitoring
- severe-hepatic-impairment
- PMID:18442638Efficacy of berberine in patients with type 2 diabetes mellitus — Metabolism, 2008
- PMID:25498346Berberine: a compound of interest in cardiovascular pharmacology — Drug Des Devel Ther, 2015
- PMID:22940174Berberine vs metformin head-to-head comparison in type 2 diabetes — Metabolism, 2012
Berberine is the over-the-counter AMPK activator. Same pathway as metformin, similar magnitude of effect on fasting glucose and HbA1c, no prescription required. The 2008 Yin et al. paper showed HbA1c reductions of 0.9% — comparable to first-line diabetic medications. The limitation is bioavailability. 5% absorption means most of the compound stays in the gut, which explains the GI side effects and the microbiome modulation. Dihydroberberine forms solve the absorption problem but cost more. Split dosing with meals is non-negotiable — single large doses cause GI distress and waste compound.
This is not medical advice
Discuss with a licensed clinician before starting, stopping, or changing any compound. This page documents what the research literature describes — it is not a prescription.
See Berberine in a protocol matched to you